Citations (32)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Linjie Li, Yu Guo, Yang Lu, Yaping Xu, Yan Lu, Xiuping Zhu, Xiaowu Dong & Jinxin Che. (2023) An updated patent review of AKT inhibitors (2020 – present). Expert Opinion on Therapeutic Patents 33:9, pages 549-564.
Read now
Read now
Wenjun Liu, Mohammad Khalid, Shadma Wahab, Mohd Faizan Siddiqui, Shaheer Hasan Khan, Mohd Sadiq & Zeenat Khatoon. (2023) A multitier virtual screening study of phytoconstituents as Myeloid Cell Leukemias 1 inhibitors. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-10.
Read now
Read now
Jingjing Liu, Fangkui Yin, Ziqian Wang, Ting Song & Zhichao Zhang. (2023) An updated patent review of Mcl-1 inhibitors (2020–2022). Expert Opinion on Therapeutic Patents 33:5, pages 371-383.
Read now
Read now
Pratik Pal, Peiyi Zhang, Saikat K. Poddar & Guangrong Zheng. (2022) Patent landscape of inhibitors and PROTACs of the anti-apoptotic BCL-2 family proteins. Expert Opinion on Therapeutic Patents 32:9, pages 1003-1026.
Read now
Read now
Steven Fletcher. (2019) MCL-1 inhibitors – where are we now (2019)?. Expert Opinion on Therapeutic Patents 29:11, pages 909-919.
Read now
Read now
Weiguo Xiang, Chao-Yie Yang & Longchuan Bai. (2018) MCL-1 inhibition in cancer treatment. OncoTargets and Therapy 11, pages 7301-7314.
Read now
Read now
Abdulrahim A. Alzain, Fatima A. Elbadwi, Rua M. Mukhtar, Tagyedeen H. Shoaib, Nihal Abdelmoniem, Samar F. Miski, Kholoud F. Ghazawi, Marwa Alsulaimany, Shaimaa G. A. Mohamed, Bayan E. Ainousah, Hazem G. A. Hussein, Gamal A. Mohamed & Sabrin R. M. Ibrahim. Design of new Mcl-1 inhibitors for cancer using fragments hybridization, molecular docking, and molecular dynamics studies. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-13.
Read now
Read now
Articles from other publishers (25)
Qineng Gong, Haojie Wang, Mi Zhou, Lu Zhou, Renxiao Wang & Yan Li. (2023) B‐cell lymphoma‐2 family proteins in the crosshairs: Small molecule inhibitors and activators for cancer therapy. Medicinal Research Reviews.
Crossref
Crossref
Li Chen, Xudong Jiang, Si Gao, Xueping Liu, Ying Gao, Audrey Siew Foong Kow, Chau Ling Tham & Ming Tatt Lee. (2022) Sensitization effect of kaempferol from persimmon leaves on HepG2 hepatoma cells with ABT-199 resistance and its molecular mechanisms. Frontiers in Pharmacology 13.
Crossref
Crossref
Ching-Lung Liao, Yi-Shih Ma, Te-Chun Hsia, Yu-Cheng Chou, Jin-Cherng Lien, Shu-Fen Peng, Chao-Lin Kuo & Fei-Ting Hsu. (2021) Tetrandrine Suppresses Human Brain Glioblastoma GBM 8401/luc2 Cell-Xenografted Subcutaneous Tumors in Nude Mice In Vivo. Molecules 26:23, pages 7105.
Crossref
Crossref
Pooja Mittal, Sujata Singh, Rajesh Sinha, Anju Shrivastava, Archana Singh & Indrakant Kumar Singh. (2021) Myeloid cell leukemia 1 (MCL-1): Structural characteristics and application in cancer therapy. International Journal of Biological Macromolecules 187, pages 999-1018.
Crossref
Crossref
Guo-dong Huang, Ping Cui, Guo-Xu Ma, Fan-fan Chen, Ze-bin Chen, Xue-juan Li, Zi-jun Liao, Wei-ping Li, Zong-yang Li & Lei Chen. (2021) Phragmunis a suppresses glioblastoma through the regulation of MCL1-FBXW7 by blocking ELK1-SRF complex-dependent transcription. Neurochemistry International 147, pages 105051.
Crossref
Crossref
Chong Li, Shiyu Feng & Ling Chen. (2020) MSC-AS1 knockdown inhibits cell growth and temozolomide resistance by regulating miR-373-3p/CPEB4 axis in glioma through PI3K/Akt pathway. Molecular and Cellular Biochemistry 476:2, pages 699-713.
Crossref
Crossref
Arvind Negi & Paul V. Murphy. (2021) Development of Mcl-1 inhibitors for cancer therapy. European Journal of Medicinal Chemistry 210, pages 113038.
Crossref
Crossref
Kexue Li. (2021) Interdiction at a protein-protein interface: MCL-1 inhibitors for oncology. Bioorganic & Medicinal Chemistry Letters 32, pages 127717.
Crossref
Crossref
Ying Fan, Xuben Hou & Hao Fang. (2020) Recent Advances in the Development of Selective Mcl-1 Inhibitors for the Treatment of Cancer (2017-Present). Recent Patents on Anti-Cancer Drug Discovery 15:4, pages 306-320.
Crossref
Crossref
Bernard Barlaam, Robert Casella, Justin Cidado, Calum Cook, Chris De Savi, Allan Dishington, Craig S. Donald, Lisa Drew, Andrew D. Ferguson, Douglas Ferguson, Steve Glossop, Tyler Grebe, Chungang Gu, Sudhir Hande, Janet Hawkins, Alexander W. Hird, Jane Holmes, James Horstick, Yun Jiang, Michelle L. Lamb, Thomas M. McGuire, Jane E. Moore, Nichole O’Connell, Andy Pike, Kurt G. Pike, Theresa Proia, Bryan Roberts, Maryann San Martin, Ujjal Sarkar, Wenlin Shao, Darren Stead, Neil Sumner, Kumar Thakur, Melissa M. Vasbinder, Jeffrey G. Varnes, Jianyan Wang, Lei Wang, Dedong Wu, Liangwei Wu, Bin Yang & Tieguang Yao. (2020) Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies. Journal of Medicinal Chemistry 63:24, pages 15564-15590.
Crossref
Crossref
Lin Lin, Dapeng Ding, Xiaoguang Xiao, Bing Li, Penglong Cao & Shijun Li. (2020) Trametinib potentiates TRAIL‐induced apoptosis via FBW7‐dependent Mcl‐1 degradation in colorectal cancer cells. Journal of Cellular and Molecular Medicine 24:12, pages 6822-6832.
Crossref
Crossref
Raoul Tibes & James M. Bogenberger. (2019) Transcriptional Silencing of MCL-1 Through Cyclin-Dependent Kinase Inhibition in Acute Myeloid Leukemia. Frontiers in Oncology 9.
Crossref
Crossref
Jian-feng Zheng, Shaozhong He, Zongyue Zeng, Xinqi Gu, Lei Cai & Guangying Qi. (2019) PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy. Molecular Therapy 27:10, pages 1784-1795.
Crossref
Crossref
Viacheslav V. Senichkin, Alena Y. Streletskaia, Boris Zhivotovsky & Gelina S. Kopeina. (2019) Molecular Comprehension of Mcl-1: From Gene Structure to Cancer Therapy. Trends in Cell Biology 29:7, pages 549-562.
Crossref
Crossref
Alexander W. Hird & Adriana E. Tron. (2019) Recent advances in the development of Mcl-1 inhibitors for cancer therapy. Pharmacology & Therapeutics 198, pages 59-67.
Crossref
Crossref
Ping Chen, Weiwu Zhan, Bin Wang, Peidong You, Qing Jin, Diyu Hou, Xiaoting Wang, Ruolan You, Hong Zou, Yuanzhong Chen & Huifang Huang. (2019) Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells. Experimental Cell Research 376:2, pages 114-123.
Crossref
Crossref
Fisayo A. Olotu, Clement Agoni, Emmanuel Adeniji, Maryam Abdullahi & Mahmoud E. Soliman. (2018) Probing Gallate-Mediated Selectivity and High-Affinity Binding of Epigallocatechin Gallate: a Way-Forward in the Design of Selective Inhibitors for Anti-apoptotic Bcl-2 Proteins. Applied Biochemistry and Biotechnology 187:3, pages 1061-1080.
Crossref
Crossref
Liang Guo, Sandy Eldridge, Michael Furniss, Jodie Mussio & Myrtle Davis. (2018) Role of Mcl-1 in regulation of cell death in human induced pluripotent stem cell-derived cardiomyocytes in vitro. Toxicology and Applied Pharmacology 360, pages 88-98.
Crossref
Crossref
Anne Slomp & Victor Peperzak. (2018) Role and Regulation of Pro-survival BCL-2 Proteins in Multiple Myeloma. Frontiers in Oncology 8.
Crossref
Crossref
Anna De Blasio, Renza Vento & Riccardo Di Fiore. (2018) Mcl‐1 targeting could be an intriguing perspective to cure cancer. Journal of Cellular Physiology 233:11, pages 8482-8498.
Crossref
Crossref
Ivie L. Conlon, Daniel Van Eker, Sameh Abdelmalak, William A. Murphy, Hassan Bashir, Michael Sun, Jay Chauhan, Kristen M. Varney, Raquel Godoy-Ruiz, Paul T. Wilder & Steven Fletcher. (2018) Kröhnke pyridines: Rapid and facile access to Mcl-1 inhibitors. Bioorganic & Medicinal Chemistry Letters 28:10, pages 1949-1953.
Crossref
Crossref
Aline D. de Araujo, Junxian Lim, Kai-Chen Wu, Yibin Xiang, Andrew C. Good, Renato Skerlj & David P. Fairlie. (2018) Bicyclic Helical Peptides as Dual Inhibitors Selective for Bcl2A1 and Mcl-1 Proteins. Journal of Medicinal Chemistry 61:7, pages 2962-2972.
Crossref
Crossref
Ying Li & Xin Wang. (2017) The role of cullin4B in human cancers. Experimental Hematology & Oncology 6:1.
Crossref
Crossref
Astrid Ruefli-Brasse & John C. Reed. (2017) Therapeutics targeting Bcl-2 in hematological malignancies. Biochemical Journal 474:21, pages 3643-3657.
Crossref
Crossref
Denis O. Okumu, Michael P. East, Merlin Levine, Laura E. Herring, Raymond Zhang, Thomas S. K. Gilbert, David W. Litchfield, Yanping Zhang & Lee M. Graves. (2017) BIRC6 mediates imatinib resistance independently of Mcl-1. PLOS ONE 12:5, pages e0177871.
Crossref
Crossref